問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Digestive System Department

Division of General Internal Medicine

Division of General Surgery

Division of Radiation Therapy

Division of Hematology & Oncology

更新時間：2023-09-19

趙毅Chao, Yee
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 11 個月

Recruiting Trial

65Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

趙毅

List

194Cases

2016-01-06 - 2018-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2014-05-01 - 2018-02-28

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2021-04-30 - 2025-04-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2021-05-07 - 2023-06-15

Phase I

A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    AMG 650

Participate Sites
3Sites

Recruiting3Sites

2021-04-01 - 2024-03-15

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-04-01 - 2023-01-31

Phase I

A Global Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of the Half-life Extended Bispecific T-cell Engager AMG 910 in Subjects With Claudin 18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

  • Condition/Disease

    Claudin 18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    AMG910

Participate Sites
2Sites

Not yet recruiting1Sites

Terminated1Sites

2019-11-01 - 2023-01-31

Phase II/III

A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cance

  • Condition/Disease

    Biliary Tract Cancer

  • Test Drug

    Bintrafusp alfa (M7824)

Participate Sites
7Sites

Recruiting7Sites

2019-10-01 - 2022-03-02

Phase III

A Phase III Open-Label, Multi-Centre, Randomised Study Comparing NUC-1031 plus Cisplatin to Gemcitabine plus Cisplatin in Patients with Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer

  • Condition/Disease

    Advanced or Metastatic Biliary Tract Cancer

  • Test Drug

    NUC-1031 for injection (Acelarin®)

Participate Sites
5Sites

Recruiting5Sites

2021-05-03 - 2022-07-07

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2018-03-01 - 2021-01-04

Phase II

RATIONALE-208: A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma

  • Condition/Disease

    Previously Treated Unresectable Hepatocellular Carcinoma

  • Test Drug

    BGB-A317

Participate Sites
6Sites

Recruiting5Sites

Terminated1Sites

侯明模
Linkou Chang Gung Medical Foundation

Division of General Internal Medicine

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

1 12 13 14 15 16 20
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB